Patents by Inventor Hiroto IWAI
Hiroto IWAI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230073999Abstract: An object of the present invention is to provide a polynucleotide having a modification site in a translated region with translation activity retained. The object can be achieved by a polynucleotide containing a translated region from a start codon to a stop codon, in which the translated region contains n codons, and the n is a positive integer of 2 or more, each of the n codons contains first, second and third nucleotides, and the first nucleotides in at least two codons of the n codons are sugar modified nucleotides.Type: ApplicationFiled: December 25, 2020Publication date: March 9, 2023Applicants: National University Corporation Tokai National Higher Education and Research System, Kyowa Kirin Co., Ltd.Inventors: Hiroshi ABE, Hiroto IWAI, Masakazu HOMMA, Kana ASANO, Kenji HARADA, Junichiro YAMAMOTO, Fumikazu SHINOHARA, Keiichi MOTOSAWA, Yasuaki KIMURA, Kosuke NAKAMOTO
-
Publication number: 20220127605Abstract: The present invention provides a nucleic acid conjugate represented by the following formula 1: wherein X is a double-stranded nucleic acid consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs, wherein in the double-stranded nucleic acid, an oligonucleotide strand having a chain length of 17 to 30 nucleotides in the antisense strand is complementary to any of target APCS mRNA sequences described in Tables 1-1 to 1-13, and the 3? end or the 5? end of the sense strand binds to S3, L1 and L2 are each independently sugar ligand, and Si, S2 and S3 are each independently a linker.Type: ApplicationFiled: December 2, 2019Publication date: April 28, 2022Applicant: KYOWA KIRIN CO., LTD.Inventors: Hiroto IWAI, Takashi IMAEDA, Hiroyuki ARIYAMA, Takuya MURAKAMI
-
Patent number: 10745700Abstract: The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.Type: GrantFiled: January 30, 2017Date of Patent: August 18, 2020Assignee: KYOWA KIRIN CO., LTD.Inventors: Keiji Uehara, Yasuhiro Suzuki, Hiroto Iwai, Masakazu Homma, Yuichi Fukuda, Tatsuto Kiuchi
-
Publication number: 20200032270Abstract: The present invention provides a nucleic acid having activity to suppress expression of MASP2, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.Type: ApplicationFiled: March 7, 2018Publication date: January 30, 2020Applicant: KYOWA KIRIN CO., LTD.Inventors: Kazuhiro MASUDA, Yoji YAMADA, Hiroto IWAI, Yuya ISODA, Wen PIAO
-
Publication number: 20190192674Abstract: The present invention provides a nucleic acid conjugate in which a sugar chain ligand is bonded to an oligonucleotide via a linker, the sugar chain ligand having O-bonded mannose at its non-reducing end.Type: ApplicationFiled: June 30, 2017Publication date: June 27, 2019Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Keiji UEHARA, Yasuhiro SUZUKI, Toshimasa HARUMOTO, Hiroto IWAI, Asana MAKINO
-
Publication number: 20190055558Abstract: The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.Type: ApplicationFiled: January 30, 2017Publication date: February 21, 2019Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Keiji UEHARA, Yasuhiro SUZUKI, Hiroto IWAI, Masakazu HOMMA, Yuichi FUKUDA, Tatsuto KIUCHI
-
Publication number: 20180208926Abstract: The present invention aims to provide a novel nucleic acid capable of suppressing expression of ?2GPI, as well as a pharmaceutical composition for the prophylaxis or treatment of diseases associated with ?2GPI expression. The present invention solves the above-mentioned problem by providing an antisense oligonucleotide having a ?2GPI expression suppressive activity, a pharmaceutical composition containing the antisense oligonucleotide, and a prophylactic or therapeutic drug for autoimmune diseases including APS, SLE and the like, and thrombosis in hemodialysis that contains the antisense oligonucleotide and suppresses ?2GPI expression.Type: ApplicationFiled: July 13, 2016Publication date: July 26, 2018Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Yoji YAMADA, Hiroto IWAI, Kazuhiro MASUDA
-
Publication number: 20180193471Abstract: The present invention provides a nucleic acid conjugate comprising: a double-stranded nucleic acid consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs; and a ligand part, wherein an oligonucleotide with a strand length of 17 to 30 nucleotides in the antisense strand is complementary to a target ?2GPI mRNA sequence, and the 3? end or 5? end of the sense strand has a ligand part represented by following formula (I), formula (II), formula (III), formula (IV) or formula (V).Type: ApplicationFiled: July 15, 2016Publication date: July 12, 2018Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Kazutaka NAGATOMO, Kazuhiro MASUDA, Minako KANDA, Yoji YAMADA, Hiroto IWAI, Asana MAKINO, Shintaro HOSOE, Takeshi KUBOYAMA, Keiji UEHARA, Yasuhiro SUZUKI
-
Publication number: 20170247701Abstract: The present invention provides a nucleic acid having activity to suppress expression of ?2GPI, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.Type: ApplicationFiled: May 13, 2017Publication date: August 31, 2017Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Yoji YAMADA, Hiroto IWAI, Kazuhiro MASUDA, Minako KANDA
-
Publication number: 20170247700Abstract: The present invention provides a nucleic acid having activity to suppress expression of ?2GPI, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.Type: ApplicationFiled: May 13, 2017Publication date: August 31, 2017Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Yoji YAMADA, Hiroto IWAI, Kazuhiro MASUDA, Minako KANDA
-
Publication number: 20160333346Abstract: The present invention provides a nucleic acid having activity to suppress expression of ?2GPI, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.Type: ApplicationFiled: January 16, 2015Publication date: November 17, 2016Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Yoji YAMADA, Hiroto IWAI, Kazuhiro MASUDA, Minako KANDA